Leading Independent Investment Research, Morningstar, Inc.

Morningstar

Leading Independent Investment Research

Morningstar, Inc.

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. We offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors. 

Morningstar provides data on more than 500,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 16 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries, with more than $180 billion in assets under advisement or management as of June 30, 2015. We have operations in 27 countries.

Download the Morningstar Fact Sheet : http://corporate.morningstar.com/US/documents/MarketingFactSheets/AboutMorningstarFactsheet.pdf

Thematic (Sector/Industry)

United states Health care / Thematic (Sector/Industry)

The history of pain drugs that target nerve growth factor has been a roller-coaster ride for drug developers and investors. In 2010, expectations were that anti-NGF drugs would emerge as the first new class of painkillers in decades, with analysts predicting $11 billion in annual sales for the multiple drugs in development. However, significant setbacks, notably the U.S. Food and Drug Administration placing clinical holds on the drugs due to safety concerns in 2010 and 2012 and the recent decision by Johnson &amp; Johnson to terminate the development of its NGF program, have resulted in investors largely writing off the value of the drug class. We view this pessimism as overdone and think that, while risky, the phase 3 programs from <a href="https://www.smartkarma.com/entities/19419" target="_blank" data-smartkarma-citation="entities:19419">Eli Lilly &amp; Co</a> and <a href="https://www.smartkarma.com/entities/1131" target="_blank" data-smartkarma-citation="entities:1131">Pfizer Inc</a> (tanezumab) and <a href="https://www.smartkarma.com/entities/9167" target="_blank" data-smartkarma-citation="entities:9167">Regeneron Pharmaceuticals</a> (fasinumab) represent significant blockbuster opportunities that are not adequately reflected in company valuations.Analysts: Damien Conover, Stefan Quenneville &amp; Sonia Vora

The history of pain drugs that target nerve growth factor has been a roller-coaster ride for drug developers and investors. In 2010, expectations were that anti-NGF drugs would emerge as the first new class of painkillers in decades, with analysts predicting $11 billion in annual sales for the multiple drugs in development. However, significant setbacks, notably the U.S. Food and Drug Administration placing clinical holds on the drugs due to safety concerns in 2010 and 2012 and the recent decision by Johnson &amp; Johnson to terminate the development of its NGF program, have resulted in investors largely writing off the value of the drug class. We view this pessimism as overdone and think that, while risky, the phase 3 programs from Eli Lilly &amp; Co and Pfizer Inc (tanezumab) and Regeneron Pharmaceuticals (fasinumab) represent significant blockbuster opportunities that are not adequately reflected in company valuations.Analysts: Damien Conover, Stefan Quenneville &amp; Sonia Vora

West Pharmaceutical Services Inc (WST US)

Mettler Toledo International Inc (MTD US)

Laboratory Corporation of America Holdings (LH US)

Laboratory Corporation of America Holdings

No Pain, Potential for Lots of Gain for Pfizer, Lilly, and Regeneron